Protherics PLC and Advancell Start Acadra(TM) Clinical Study in B-cell Chronic Lymphocytic Leukaemia

Published: Jan 11, 2008

London, UK; Brentwood, TN, US; 11 January 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, and its co-development partner, Advancell s.l. ("Advancell"), today announce that the first patient has now been enrolled in a recently initiated phase 1/2 clinical study of Acadra(TM) (acadesine) in B-cell chronic lymphocytic leukaemia (B-CLL).

Back to news